Stock EMMA EMMAUS LIFE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Emmaus Life Sciences, Inc.

Equities

EMMA

US29137T1016

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 12:53:55 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.1 USD -.--% Intraday chart for Emmaus Life Sciences, Inc. +8.58% -0.10%
Feb. 02 Emmaus Life Sciences, Inc. Receives Marketing Authorization from the Puerto Rico Department of Health for Endari® (L-Glutamine Oral Powder) CI
2023 Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q3 Revenue $5M MT

Valuation

Fiscal Period: December 2019 2020 2021 2022
Capitalization 1 95.49 60.25 82.35 12.9
Enterprise Value (EV) 1 85.27 76.75 102.5 41.7
P/E ratio -1.52 x 54.7 x -5.16 x -1.21 x
Yield - - - -
Capitalization / Revenue 4.2 x 2.6 x 4 x 0.7 x
EV / Revenue 3.75 x 3.31 x 4.97 x 2.27 x
EV / EBITDA -41.8 x 2,741 x -16.9 x -6.38 x
EV / FCF -216 x -34.2 x 9.85 x 9.36 x
FCF Yield -0.46% -2.93% 10.2% 10.7%
Price to Book -8.64 x -11.1 x -3.84 x -0.38 x
Nbr of stocks (in thousands) 48,471 48,987 49,312 49,559
Reference price 2 1.970 1.230 1.670 0.2603
Announcement Date 1/25/21 5/4/21 3/31/22 3/31/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.5134 15.08 22.75 23.17 20.61 18.39
EBITDA 1 -18.86 -10.04 -2.039 0.028 -6.069 -6.533
EBIT 1 -18.89 -10.1 -2.112 -0.032 -6.128 -6.586
Operating Margin -3,679.03% -66.99% -9.28% -0.14% -29.73% -35.81%
Earnings before Tax (EBT) 1 -45.67 -58.04 -54.68 0.719 -15.92 -10.56
Net income 1 -33.37 -57.9 -54.84 1.1 -15.95 -10.62
Net margin -6,499.42% -384.02% -241.04% 4.75% -77.37% -57.78%
EPS 2 -0.9592 -1.650 -1.298 0.0225 -0.3238 -0.2149
Free Cash Flow 1 16.67 -14.75 -0.3956 -2.246 10.4 4.453
FCF margin 3,245.96% -97.86% -1.74% -9.7% 50.48% 24.21%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/16/18 3/21/19 1/25/21 5/4/21 3/31/22 3/31/23
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales 1 3.02 3.234 4.287 4.939 5.93 6.753
EBITDA - - - - - -
EBIT -4.965 - - - - -
Operating Margin -164.4% - - - - -
Earnings before Tax (EBT) - - - - - -
Net income - - - - - -
Net margin - - - - - -
EPS - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/31/22 5/13/22 8/15/22 11/14/22 3/31/23 5/15/23
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - 16.5 20.1 28.8
Net Cash position 1 78.3 28.2 10.2 - - -
Leverage (Debt/EBITDA) - - - 589.3 x -3.317 x -4.408 x
Free Cash Flow 1 16.7 -14.8 -0.4 -2.25 10.4 4.45
ROE (net income / shareholders' equity) 2,040% 7,239% 335% -13.4% 120% 38.3%
ROA (Net income/ Total Assets) -17.3% -6.36% -1.96% -0.03% -6.59% -7.84%
Assets 1 193.4 909.9 2,799 -3,274 242 135.5
Book Value Per Share 2 0.4100 -0.4400 -0.2300 -0.1100 -0.4300 -0.6900
Cash Flow per Share 2 0.4500 0.4800 0.0400 0.0500 0.0500 0.0400
Capex 1 0.09 0.09 0.06 0.02 0.07 0.03
Capex / Sales 17.54% 0.62% 0.26% 0.06% 0.35% 0.14%
Announcement Date 4/16/18 3/21/19 1/25/21 5/4/21 3/31/22 3/31/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EMMAUS LIFE SCIENCES, INC. Stock Emmaus Life Sciences, Inc.
-0.10% 6.18M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.86B
MODERNA, INC. Stock Moderna, Inc.
+10.92% 42.74B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 41.36B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 27.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 25.15B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.63B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 11.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EMMA Stock
  4. Financials Emmaus Life Sciences, Inc.